Last reviewed · How we verify
3-Butylphthalide (Butylphthalide)
At a glance
| Generic name | Butylphthalide |
|---|---|
| Also known as | 3-n-Butylphthalide, NBP, DL-3-n-butylphthalide, dl-NBP, Blank |
| Sponsor | CSPC Ouyi Pharmaceutical |
| Target | Potassium channel subfamily K member 2 |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
Approved indications
- Ischemic stroke
Common side effects
Key clinical trials
- Efficacy and Safety of Butylphthalide Soft Capsule for the Treatment of Vascular Dementia (PHASE3)
- Effects of Butylphthalide Enhanced With Tenecteplase on Neurological Function in Mild Disabling Acute Ischemic Stroke (PHASE3)
- Isosorbide Mononitrate and Butylphthalide to Reduce the Risk of Disability in Patients With Acute Lacunar Stroke (IMPACT) (PHASE3)
- Efficacy and Safety of Early Initiation of Butylphthalide Treatment in Patients With Acute Ischemic Stroke. (PHASE2)
- Butylphthalide for Long-term Efficacy in Minor Stroke Study (PHASE3)
- Butylphthalide for Cognitive Impairment in Elderly Patients With Focal Epilepsy (PHASE4)
- FHND1002 for ALS Treatment: Phase 2 (PHASE2)
- Intra-arterial Neuroprotective Strategy for Ischemic STroke Patients With Endovascular Therapy (INSIST-ET) (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 3-Butylphthalide CI brief — competitive landscape report
- 3-Butylphthalide updates RSS · CI watch RSS
- CSPC Ouyi Pharmaceutical portfolio CI